Seroquel Patent Expiration Leads To Sharp 2Q Revenue Decline For AstraZeneca
This article was originally published in The Pink Sheet Daily
With U.S. revenues down 29% and the EU take off by 20%, perhaps AstraZeneca’s greatest concern is only 1% revenue growth in emerging markets, which the pharma has targeted as a key revenue-driver through its patent cliff.
You may also be interested in...
A new debate among investors concerns whether double-digit growth is possible across emerging markets or only in China. PharmAsia News takes a closer look.
With the longtime CEO stepping down as of June 1, his successor will assume the challenge of handling generic challengers to several mature blockbuster products and the slow launch of Brilinta. The current business-development strategy, as reflected in a recent partnership and acquisition, is expected to stay in place for now.
A rough first quarter and news of the CEO’s decision to step down in slightly over a month leads to speculation that AstraZeneca could be an attractive M&A target for another pharma that might shut down the company’s struggling R&D effort and cash in on the existing portfolio.